Literature DB >> 27129209

E2 Ubiquitin-conjugating Enzyme, UBE2C Gene, Is Reciprocally Regulated by Wild-type and Gain-of-Function Mutant p53.

Swati Bajaj1, Sk Kayum Alam2, Kumar Singha Roy2, Arindam Datta2, Somsubhra Nath3, Susanta Roychoudhury4.   

Abstract

Spindle assembly checkpoint governs proper chromosomal segregation during mitosis to ensure genomic stability. At the cellular level, this event is tightly regulated by UBE2C, an E2 ubiquitin-conjugating enzyme that donates ubiquitin to the anaphase-promoting complex/cyclosome. This, in turn, facilitates anaphase-onset by ubiquitin-mediated degradation of mitotic substrates. UBE2C is an important marker of chromosomal instability and has been associated with malignant growth. However, the mechanism of its regulation is largely unexplored. In this study, we report that UBE2C is transcriptionally activated by the gain-of-function (GOF) mutant p53, although it is transcriptionally repressed by wild-type p53. We showed that wild-type p53-mediated inhibition of UBE2C is p21-E2F4-dependent and GOF mutant p53-mediated transactivation of UBE2C is NF-Y-dependent. We further explored that DNA damage-induced wild-type p53 leads to spindle assembly checkpoint arrest by repressing UBE2C, whereas mutant p53 causes premature anaphase exit by increasing UBE2C expression in the presence of 5-fluorouracil. Identification of UBE2C as a target of wild-type and GOF mutant p53 further highlights the contribution of p53 in regulation of spindle assembly checkpoint.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  E2F transcription factor; mitosis; mitotic spindle; p53; ubiquitin-conjugating enzyme (E2 enzyme)

Mesh:

Substances:

Year:  2016        PMID: 27129209      PMCID: PMC4933179          DOI: 10.1074/jbc.M116.731398

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

Authors:  Silvia Di Agostino; Sabrina Strano; Velia Emiliozzi; Valentina Zerbini; Marcella Mottolese; Ada Sacchi; Giovanni Blandino; Giulia Piaggio
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

2.  B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells.

Authors:  Mirijam Mannefeld; Elena Klassen; Stefan Gaubatz
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

Review 3.  Blinded by the Light: The Growing Complexity of p53.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

4.  CDF-1-mediated repression of cell cycle genes targets a specific subset of transactivators.

Authors:  J Zwicker; F C Lucibello; V Jérôme; S Brüsselbach; R Müller
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

5.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

Review 6.  A survey of 178 NF-Y binding CCAAT boxes.

Authors:  R Mantovani
Journal:  Nucleic Acids Res       Date:  1998-03-01       Impact factor: 16.971

7.  p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest.

Authors:  Jenny S L Ho; Weili Ma; Daniel Y L Mao; Samuel Benchimol
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

8.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.

Authors:  G Blandino; A J Levine; M Oren
Journal:  Oncogene       Date:  1999-01-14       Impact factor: 9.867

9.  Cdk2-dependent phosphorylation of the NF-Y transcription factor is essential for the expression of the cell cycle-regulatory genes and cell cycle G1/S and G2/M transitions.

Authors:  Hee-Don Chae; Jeanho Yun; Yung-Jue Bang; Deug Y Shin
Journal:  Oncogene       Date:  2004-05-20       Impact factor: 9.867

10.  p53 can repress transcription of cell cycle genes through a p21(WAF1/CIP1)-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements.

Authors:  Marianne Quaas; Gerd A Müller; Kurt Engeland
Journal:  Cell Cycle       Date:  2012-11-27       Impact factor: 4.534

View more
  13 in total

1.  p53 gain-of-function mutations increase Cdc7-dependent replication initiation.

Authors:  Arindam Datta; Dishari Ghatak; Sumit Das; Taraswi Banerjee; Anindita Paul; Ramesh Butti; Mahadeo Gorain; Sangeeta Ghuwalewala; Anirban Roychowdhury; Sk Kayum Alam; Pijush Das; Raghunath Chatterjee; Maitrayee Dasgupta; Chinmay Kumar Panda; Gopal C Kundu; Susanta Roychoudhury
Journal:  EMBO Rep       Date:  2017-09-08       Impact factor: 8.807

2.  Comparison of gene expression response to neutron and x-ray irradiation using mouse blood.

Authors:  Constantinos G Broustas; Yanping Xu; Andrew D Harken; Guy Garty; Sally A Amundson
Journal:  BMC Genomics       Date:  2017-01-03       Impact factor: 3.969

3.  Identification of a p53-repressed gene module in breast cancer cells.

Authors:  Takafumi Miyamoto; Chizu Tanikawa; Varalee Yodsurang; Yao-Zhong Zhang; Seiya Imoto; Rui Yamaguchi; Satoru Miyano; Hidewaki Nakagawa; Koichi Matsuda
Journal:  Oncotarget       Date:  2017-07-26

4.  Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.

Authors:  Sandra Martínez-Canales; Miguel López de Rodas; Miriam Nuncia-Cantarero; Raquel Páez; Eitan Amir; Balázs Győrffy; Atanasio Pandiella; Eva María Galán-Moya; Alberto Ocaña
Journal:  Cancer Med       Date:  2018-03-25       Impact factor: 4.452

5.  UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1.

Authors:  Pedro Nicolau-Neto; Antonio Palumbo; Marco De Martino; Francesco Esposito; Tatiana de Almeida Simão; Alfredo Fusco; Luiz Eurico Nasciutti; Nathalia Meireles Da Costa; Luis Felipe Ribeiro Pinto
Journal:  Genes (Basel)       Date:  2018-03-29       Impact factor: 4.096

6.  UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells.

Authors:  Yu Xiong; Jing Lu; Qinliang Fang; Yuyan Lu; Chengrong Xie; Huita Wu; Zhenyu Yin
Journal:  Biosci Rep       Date:  2019-04-17       Impact factor: 3.840

7.  Identification of key candidate genes and pathways in endometrial cancer: Evidence from bioinformatics analysis.

Authors:  Sha Lv; Xiaoxiao Xu; Zhangying Wu
Journal:  Oncol Lett       Date:  2019-11-01       Impact factor: 2.967

Review 8.  Cancer Stemness: p53 at the Wheel.

Authors:  Dishari Ghatak; Damayanti Das Ghosh; Susanta Roychoudhury
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

9.  Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53.

Authors:  Arindam Datta; Pijush Das; Sanjib Dey; Sangeeta Ghuwalewala; Dishari Ghatak; Sk Kayum Alam; Raghunath Chatterjee; Susanta Roychoudhury
Journal:  Genes (Basel)       Date:  2019-10-28       Impact factor: 4.096

Review 10.  More than Meets the ISG15: Emerging Roles in the DNA Damage Response and Beyond.

Authors:  Zac Sandy; Isabelle Cristine da Costa; Christine K Schmidt
Journal:  Biomolecules       Date:  2020-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.